<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Swanton, Charles</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Better Molecular Profiling is Needed for Rational, Targeted Therapy in CRC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-23</style></pages><abstract><style  face="normal" font="default" size="100%">Colorectal cancer (CRC) was one the first solid malignancies to be classified using molecular profiling, and led to the identification of critical genes and pathways involved in this disease. This article discusses future directions of biomarker research, the molecular biomarker characterization and subtyping of CRC, and the implications of tumor heterogeneity.</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>